VERU INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
VERU INC. (VERU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.72 million shares for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-10
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 2.36M shares.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 350.70K shares, a 46.12% increase year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 184.00K shares, a 92.54% decline from fiscal 2024.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.47M shares.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 2.72M shares, a 15461.74% increase from fiscal 2016.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 17.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.36M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | 2.36M shares derived: sum of 2 quarters · filed 2026-08-10 | 2.72M shares 10-Q · filed 2026-08-10 | 2.72M shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | 350.70K shares 10-Q · filed 2026-05-13 | 350.70K shares derived: sum of 3 quarters · filed 2026-05-13 | 279.70K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 350.70K shares 10-Q · filed 2026-02-11 | 350.70K shares derived: sum of 2 quarters · filed 2026-02-11 | 279.70K shares derived: sum of 3 quarters · filed 2026-02-11 | 294.70K shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -71.00K shares derived: sum of 2 quarters · filed 2025-12-17 | -56.00K shares derived: sum of 3 quarters · filed 2025-12-17 | 184.00K shares 10-K · filed 2025-12-17 |
| 2025-06-30 | -71.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | -56.00K shares derived: sum of 2 quarters · filed 2025-08-12 | 184.00K shares 10-Q · filed 2025-08-12 | 370.48K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 15.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-08 | 255.00K shares 10-Q · filed 2025-05-08 | 441.48K shares derived: sum of 3 quarters · filed 2025-05-08 | |
| 2024-12-31 | 240.00K shares 10-Q · filed 2025-02-13 | 426.48K shares derived: sum of 2 quarters · filed 2025-02-13 | ||
| 2024-09-30 | 186.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | 2.47M shares 10-K · filed 2024-12-16 | ||
| 2024-06-30 | 2.28M shares 10-Q · filed 2024-08-08 | |||
| 2020-06-30 | 0.00 shares 10-Q · filed 2020-08-13 | |||
| 2017-09-30 | 2.72M shares 10-K · filed 2018-01-02 | |||
| 2016-09-30 | 17.50K shares 10-K · filed 2018-01-02 | |||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-04-28 | 0.00 shares 10-Q · filed 2016-04-28 | ||
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-04-28 | 0.00 shares 10-Q · filed 2016-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |